The Importance of Understanding Clinical Trial Design as a Medtech CEO: Interview with Nadim Yared, CEO of CVRx

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded04 Mar 2021

Publisherfeeds.transistor.fm ↗

Handlerec:13866361

Show notes

In this episode of Medsider Radio, we’re talking with Nadim Yared, the CEO of CVRx, a pioneer in neuromodulation for cardiovascular diseases. Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re going to discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA & CMS. But first, here’s a bit more about Nadim Yared and his background: Nadim holds two graduate degrees, and started his career with GE. After getting his MBA at INSEAD, he went on to run several business units for GE, then spent four years as the head of Medtronic’s Surgical Navigation division. Nadim was then recruited to take the helm at CVRx in 2006, and has been CEO ever since. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Nadim Yared if you'd rather read it instead.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.